LICENSE AGREEMENTS (Details)	1 Months Ended					3 Months Ended
	Jul. 31, 2020 USD ($)	Jul. 31, 2019 USD ($)	Apr. 30, 2018 USD ($)	May 31, 2016 USD ($)	Dec. 31, 2012 USD ($)	Mar. 31, 2021 USD ($) item	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Nov. 30, 2012 USD ($)
Revenue						$ 793,000	$ 38,000
Eligible payments to be received						55,583,000	34,043,000
TG-1101 [Member]
Upfront fee				$ 5,000,000.0	$ 2,000,000.0
Income taxes					$ 300,000
Revenue						38,000	38,000
Term after first commercial sale					15 years
Deferred Revenue						700,000		$ 800,000
Deferred Revenue, Current						100,000		$ 100,000
TG-1701 [Member]
Upfront fee		$ 100,000	$ 1,000,000.0			350,000,000
Manufacturing expense						500,000	800,000
Milestone payment made	$ 2,000,000.0
TG-1801 [Member]
Upfront fee						3,000,000.0
Additional payments on achievement of certain milestones									$ 185,000,000
Expenses incurred						2,000,000.0
Tgr 1202 Umbralisib [Member]
Royalty Expense						100,000
TGR-1202 [Member]
Additional payments on achievement of certain milestones						175,000,000
Milestone payment made						$ 12,000,000.0
Number of oncology indications | item						2
Number of non oncology indications | item						1
TG 1501 [Member]
Expenses incurred						$ 0	$ 900,000
Umbralisib License Agreement [Member] | Tgr 1202 Umbralisib [Member]
Royalty Expense						100,000
LFB Group [Member] | LFB License Agreement
Eligible payments to be received						31,000,000.0
Additional payments on achievement of certain milestones						$ 3,000,000.0
Operating lease initial commitment period						15 years
Expenses incurred						$ 3,000,000.0